Entrada Therapeutics, Inc.(TRDA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TRDA Entrada Therapeutics, Inc.

交易中 05-29 11:21:30 EDT

6.87

+0.05

+0.73%

最高6.90	最低6.75	成交量8.02万
今开6.82	昨收6.82	日振幅2.25%
总市值2.67亿	流通市值1.69亿	总股本3,882万
成交额54.94万	换手率0.33%	流通股本2,454万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TRDA","market":"US","secType":"STK","nameCN":"Entrada Therapeutics, Inc.","latestPrice":6.87,"timestamp":1780068032590,"preClose":6.82,"halted":0,"volume":80181,"delay":0,"changeRate":0.007331378299120208,"floatShares":24538200,"shares":38820616,"eps":-3.99686,"marketStatus":"交易中","change":0.05,"latestTime":"05-29 11:21:30 EDT","open":6.82,"high":6.9034,"low":6.75,"amount":549439.821414,"amplitude":0.022493,"askPrice":6.89,"askSize":4,"bidPrice":6.86,"bidSize":153,"shortable":3,"etf":0,"ttmEps":-3.99686,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1780084800000},"marketStatusCode":2,"adr":0,"listingDate":1635480000000,"exchange":"NASDAQ","adjPreClose":6.82,"preHourTrading":{"tag":"盘前","latestPrice":6.82,"preClose":6.82,"latestTime":"08:17 EDT","volume":116,"amount":777.9799840000001,"timestamp":1780057062486,"change":0,"changeRate":0,"amplitude":0.033724},"postHourTrading":{"tag":"盘后","latestPrice":6.82,"preClose":6.82,"latestTime":"19:06 EDT","volume":1873,"amount":12768.95,"timestamp":1780009616290,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.70171,"impliedVol":1.1593,"impliedVolPercentile":0.6375},"requestUrl":"/m/hq/s/TRDA","defaultTab":"news","newsList":[{"id":"1151372775","title":"Entrada Therapeutics：队列1治疗组外显子跳跃率较基线2.66%提升2.31个百分点","url":"https://stock-news.laohu8.com/highlight/detail?id=1151372775","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151372775?lang=zh_cn&edition=full","pubTime":"2026-05-07 19:06","pubTimestamp":1778151973,"startTime":"0","endTime":"0","summary":"生物技术公司Entrada Therapeutics公布最新临床数据，其针对杜氏肌营养不良症的实验性疗法在队列1研究中取得积极进展。数据显示，接受治疗的患者外显子跳跃率较基线水平2.66%实现2.31个百分点的显著提升，这一指标对评估基因疗法疗效具有关键意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153611846","title":"Entrada Therapeutics：I/II期Elevate-44-201研究首批队列达成主要终点 安全性及耐受性表现良好","url":"https://stock-news.laohu8.com/highlight/detail?id=1153611846","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153611846?lang=zh_cn&edition=full","pubTime":"2026-05-07 19:06","pubTimestamp":1778151972,"startTime":"0","endTime":"0","summary":"生物技术公司Entrada Therapeutics宣布，其针对杜氏肌营养不良症治疗的I/II期临床研究Elevate-44-201完成首批患者队列评估。数据显示，该试验成功达成主要研究目标，药物安全性及耐受性特征呈现积极结果。\n此次突破性进展为ENCO-44候选药物的后续开发奠定重要基础。研究团队观察到患者对治疗方案的响应符合预期，未出现重大不良反应。这一里程碑标志着公司在外显子跳跃疗法领域取得关键技术进步。\n下一步，Entrada将基于首批队列的积极数据，加快推进后续患者入组及剂量探索工作。公司计划在近期学术会议中公布详细临床结果，为行业提供新的治疗思路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106702464","title":"Entrada Therapeutics：治疗组参与者在起身速度指标上呈现统计学显著且具潜在差异化的改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1106702464","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106702464?lang=zh_cn&edition=full","pubTime":"2026-05-07 19:06","pubTimestamp":1778151972,"startTime":"0","endTime":"0","summary":"Entrada Therapeutics公布的最新研究数据显示，与安慰剂组相比，接受其治疗方案的患者群体在\"起身速度\"这一关键指标上表现出统计学上的显著改善，且该改善效果展现出潜在的差异化优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TRDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167503181","title":"Entrada Therapeutics首组治疗参与者抗肌萎缩蛋白水平较4.00%基线提升2.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=1167503181","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167503181?lang=zh_cn&edition=full","pubTime":"2026-05-07 19:03","pubTimestamp":1778151828,"startTime":"0","endTime":"0","summary":"生物技术公司Entrada Therapeutics公布其临床试验首组数据显示，接受治疗的患者群体抗肌萎缩蛋白表达水平呈现显著改善。具体而言，该组患者抗肌萎缩蛋白水平较4.00%的基线值实现了2.36个百分点的增长。\n这一阶段性成果标志着公司在神经肌肉疾病治疗领域取得重要进展。抗肌萎缩蛋白的增幅数据为评估疗法有效性提供了关键量化依据，也为后续临床研究奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132626820","title":"Entrada Therapeutics启动Elevate-44-201研究第二队列给药 剂量提升至12毫克/千克 预计2026年底前公布数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1132626820","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132626820?lang=zh_cn&edition=full","pubTime":"2026-05-07 19:03","pubTimestamp":1778151795,"startTime":"0","endTime":"0","summary":"生物制药公司Entrada Therapeutics（股票代码：TRDA）宣布，其Elevate-44-201临床研究的第二队列患者给药已正式启动。此次给药采用了提升后的12毫克/千克剂量方案。\n该公司明确表示，这项临床研究进展顺利，完全按计划推进。所有研究工作正稳步进行，预计将在2026年底前获得并公布相关临床数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TRDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185535827","title":"Entrada Therapeutics将于2026年5月7日公布Elevate-44-201研究队列1中杜氏肌营养不良症患者接受Entr-601-44治疗的初步结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1185535827","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185535827?lang=zh_cn&edition=full","pubTime":"2026-05-07 04:30","pubTimestamp":1778099429,"startTime":"0","endTime":"0","summary":"Entrada Therapeutics公司宣布，将于2026年5月7日正式披露其Elevate-44-201一期/二期临床试验中首个队列的初步研究数据。该队列由接受实验性疗法Entr-601-44治疗的杜氏肌营养不良症患者组成。此次公布的结果将重点关注药物的安全性和有效性指标，为后续临床开发提供关键依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TRDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140741050","title":"Entrada Therapeutics计划2026年底前启动ENTR-601-50全球1/2期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1140741050","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140741050?lang=zh_cn&edition=full","pubTime":"2026-01-08 20:12","pubTimestamp":1767874341,"startTime":"0","endTime":"0","summary":"生物技术公司Entrada Therapeutics宣布，预计将在2026年年底前启动其候选药物ENTR-601-50的全球性1/2期多次给药（MAD）临床研究。这一时间表标志着该公司在推进其研发管线方面迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TRDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161618850","title":"Entrada Therapeutics公司预计2026年第二季度公布Elevate-44-201首组数据，年中披露Elevate-45-201首组数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1161618850","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161618850?lang=zh_cn&edition=full","pubTime":"2026-01-08 20:10","pubTimestamp":1767874239,"startTime":"0","endTime":"0","summary":"生物技术公司Entrada Therapeutics Inc（TRDA）宣布其临床研究计划正稳步推进。根据最新时间表，公司将在2026年第二季度公布Elevate-44-201试验首组患者的研究数据，并于2026年年中发布Elevate-45-201试验的首组数据。这两项关键临床数据的披露将为企业后续研发决策提供重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142220963","title":"Entrada Therapeutics 2024年第四季度GAAP每股收益$0.03超过预期$(0.67)，销售额$37.40M超过预期$13.12M","url":"https://stock-news.laohu8.com/highlight/detail?id=1142220963","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142220963?lang=zh_cn&edition=full","pubTime":"2025-02-27 20:12","pubTimestamp":1740658350,"startTime":"0","endTime":"0","summary":"Entrada Therapeutics  公布季度每股收益为$0.03，超过分析师一致预期$，超出104.48%。公司季度销售额为$37.40百万，超过分析师一致预期的$13.12百万，超出185.04%。与去年同期$41.85百万的销售额相比，减少了10.63%。以上内容来自Benzinga Earnings专栏，原文如下：Entrada $Therapeutics$  reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $ by 104.48 percent. This is a 110.34 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $37.40 million which beat the analyst consensus estimate of $13.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRDA","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2478372279","title":"Entrada Therapeutics, Inc.盘中异动 早盘股价大涨5.23%报17.72美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2478372279","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478372279?lang=zh_cn&edition=full","pubTime":"2024-10-25 23:07","pubTimestamp":1729868847,"startTime":"0","endTime":"0","summary":"北京时间2024年10月25日23时07分，Entrada Therapeutics, Inc.股票出现波动，股价大幅拉升5.23%。Entrada Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.85%。Entrada Therapeutics, Inc.公司简介：Entrada Therapeutics Inc临床阶段生物制药公司，旨在通过建立一类新的药物来改变患者的生活，这些药物涉及长期以来被认为难以接近的细胞内靶点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102523072798e3e89c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102523072798e3e89c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","TRDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.entradatx.com;ir.entradatx.com","stockEarnings":[{"period":"1week","weight":0.0808},{"period":"1month","weight":-0.4709},{"period":"3month","weight":-0.4283},{"period":"6month","weight":-0.3359},{"period":"1year","weight":-0.1223},{"period":"ytd","weight":-0.3366}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0603},{"period":"3month","weight":0.1},{"period":"6month","weight":0.1042},{"period":"1year","weight":0.2839},{"period":"ytd","weight":0.1066}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Entrada Therapeutics, Inc.于2016年9月22日根据特拉华州法律注册成立。该公司旨在通过将内体逃逸载体(EEV)疗法确立为一种新型药物来改变患者的生活，并致力于成为世界上最重要的细胞内疗法公司。该公司的EEV疗法旨在处理长期以来被认为无法接近和无法成药的细胞内靶标。通过其专有的、高度通用的模块化EEV平台，该公司正在构建强大的EEV治疗候选药物开发组合，旨在使治疗剂在各种器官和组织中有效细胞内递送，并提高治疗指数。该公司相信，早期项目的潜在成功可以转化为有效开发其他EEV治疗候选药物，并能够在罕见疾病、免疫学和肿瘤学方面建立投资组合。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.119802},{"month":2,"riseRate":0.6,"avgChangeRate":-0.003122},{"month":3,"riseRate":0.6,"avgChangeRate":-0.040525},{"month":4,"riseRate":0.4,"avgChangeRate":-0.127921},{"month":5,"riseRate":0.4,"avgChangeRate":-0.049565},{"month":6,"riseRate":0.5,"avgChangeRate":0.23206},{"month":7,"riseRate":0.75,"avgChangeRate":0.057246},{"month":8,"riseRate":0.25,"avgChangeRate":-0.040222},{"month":9,"riseRate":0.75,"avgChangeRate":0.071087},{"month":10,"riseRate":1,"avgChangeRate":0.182556},{"month":11,"riseRate":0.6,"avgChangeRate":0.06971},{"month":12,"riseRate":0.4,"avgChangeRate":-0.097654}],"exchange":"NASDAQ","name":"Entrada Therapeutics, Inc.","nameEN":"Entrada Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Entrada Therapeutics, Inc.(TRDA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Entrada Therapeutics, Inc.(TRDA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Entrada Therapeutics, Inc.,TRDA,Entrada Therapeutics, Inc.股票,Entrada Therapeutics, Inc.股票老虎,Entrada Therapeutics, Inc.股票老虎国际,Entrada Therapeutics, Inc.行情,Entrada Therapeutics, Inc.股票行情,Entrada Therapeutics, Inc.股价,Entrada Therapeutics, Inc.股市,Entrada Therapeutics, Inc.股票价格,Entrada Therapeutics, Inc.股票交易,Entrada Therapeutics, Inc.股票购买,Entrada Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Entrada Therapeutics, Inc.(TRDA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Entrada Therapeutics, Inc.(TRDA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}